(PLRX) Pliant Therapeutics - Ratings and Ratios

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering novel therapies for fibrotic diseases. Its pipeline centers on targeting integrin biology, a critical driver of fibrosis. The companys lead candidate, bexotegrast, is a dual selective inhibitor of avß6 and avß1 integrins, advancing through Phase 2b trials for idiopathic pulmonary fibrosis (IPF) and Phase 2a for primary sclerosing cholangitis (PSC). Additionally, PLN-1474 targets liver fibrosis in nonalcoholic steatohepatitis (NASH), while PLN-101095 and PLN-101325 address solid tumors and muscular dystrophies, respectively. Since its inception in 2015, Pliant has established a robust presence in South San Francisco, California.

Technically, PLRX shows a bearish trend with its price ($1.38) below the 20-day SMA ($4.95), 50-day SMA ($9.37), and 200-day SMA ($12.02). The average volume of 4.9 million and ATR of $0.84 suggest moderate volatility. On the fundamental side, with a market cap of $198.38M, PLRX trades at a P/S of 3050.34, indicating high valuation relative to sales. The negative RoE (-58.32%) reflects ongoing losses, while the P/B of 0.55 points to undervaluation relative to book value.

3-Month Forecast: The stock may face downward pressure due to its current bearish momentum and high valuation multiples. However, positive Phase 2 trial results for bexotegrast could act as a catalyst for upside. Expect volatility with potential price swings between $1.00 and $1.80, influenced by trial outcomes and broader market sentiment.